Weight Loss, Body Fat Mass, and Leptin in Parkinson's Disease

被引:68
|
作者
Lorefalt, Birgitta [1 ]
Toss, Goran [2 ]
Granerus, Ann-Kathrine [3 ]
机构
[1] Linkoping Univ, Dept Med & Hlth Sci, Div Nursing Sci, Fac Hlth Sci, SE-58185 Linkoping, Sweden
[2] Linkoping Univ, Fac Hlth Sci, Div Internal Med, SE-58185 Linkoping, Sweden
[3] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Geriatr, SE-58185 Linkoping, Sweden
关键词
Parkinson's disease; body weight; body fat mass; leptin; ELDERLY-PATIENTS;
D O I
10.1002/mds.22466
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Weight loss is a common problem in Parkinson's disease (PD), but the causative mechanisms behind this weight loss are unclear. We compared 2( PD patients with sex and age matched healthy controls. Examinations were repeated at baseline, after one and after two years. Body fat mass was measured by Dual X-ray Absorptiometry (DXA). Seventy three per cent of the PD patients lost body weight. Loss of body fat mass constituted a considerable part of the loss of body weight. In the patients who lost weight, serum leptin levels were lower than in those who did not lose weight. The relationship between low body fat mass and low leptin levels seems to be relevant, at least for female PD patients. It is reasonable to believe that low leptin levels in these patients could be secondary to the decreased body fat mass. (C) 2009 Movement Disorder Society
引用
下载
收藏
页码:885 / 890
页数:6
相关论文
共 50 条
  • [41] Adipocyte apoptosis in the regulation of body fat mass by leptin
    Della-Fera, MA
    Qian, H
    Baile, CA
    DIABETES OBESITY & METABOLISM, 2001, 3 (05): : 299 - 310
  • [42] Body mass index, change in body mass index and risk of Parkinson's disease
    Lee, J.
    Kim, J. H.
    Cho, J. H.
    Kim, G. S.
    Lee, J. H.
    Lee, P. H.
    Sohn, Y. H.
    MOVEMENT DISORDERS, 2017, 32
  • [43] LEAN BODY MASS INCREASES, BODY FAT DECREASES DURING WEIGHT MAINTENANCE FOLLOWING WEIGHT LOSS IN OBESE DOGS
    MacLeay, Jen
    Hahn, Kevin
    Melendez, Lynda
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2013, 27 (03) : 743 - 743
  • [44] GHRELIN AND LEPTIN LEVELS IN RELATION TO BODY FAT MASS IN CHILDREN WITH CHRONIC KIDNEY DISEASE
    Canpolat, Nur
    AgbaS, Ayse
    Oruc, Cigdem
    Ekmekci, Ozlem Balci
    Sever, Fatma Lale
    Caliskan, Salim
    PEDIATRIC NEPHROLOGY, 2017, 32 (09) : 1684 - 1685
  • [45] Serum leptin in obesity is related to gender and body fat topography but does not predict successful weight loss
    Niskanen, LK
    Haffner, S
    Karhunen, LJ
    Turpeinen, AK
    Miettinen, H
    Uusitupa, MIJ
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (01) : 61 - 67
  • [46] Body weight and body mass index changes after subthalamic nucleus deep brain stimulation in Parkinson's disease
    Kim, S. -R.
    Chung, S. -J.
    Kim, M. -J.
    Kim, M. -S.
    Lee, M. -C.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S166 - S167
  • [47] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    Arabia, G
    Zappia, M
    Bosco, D
    Crescibene, L
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Scornaienghi, M
    Quattrone, A
    NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) : S53 - S54
  • [48] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    G. Arabia
    M. Zappia
    D. Bosco
    L. Crescibene
    A. Bagalà
    L. Bastone
    M. Caracciolo
    M. Scornaienghi
    A. Quattrone
    Neurological Sciences, 2002, 23 : s53 - s54
  • [49] Body weight determinants in Parkinson's disease: A multifactorial study
    Bril, A.
    Rossi, M.
    Farina, S.
    Morisset, P.
    Sorrentino, L.
    Iglesias, M.
    Medina Escobar, A.
    Millar Vernetti, P.
    Cerquetti, D.
    Perez Lloret, S.
    Merello, M.
    MOVEMENT DISORDERS, 2016, 31 : S99 - S99
  • [50] Body weight influences pharmacokinetics of levodopa in Parkinson's disease
    Zappia, M
    Crescibene, L
    Arabia, G
    Nicoletti, G
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Bonavita, S
    Di Costanzo, A
    Scornaienchi, M
    Gambardella, A
    Quattrone, A
    CLINICAL NEUROPHARMACOLOGY, 2002, 25 (02) : 79 - 82